| 1. |
Eiichi Ogawa, Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B can increase body weight-Authors' reply, Alimentary Pharmacology and Therapeutics, doi: 10.1111/apt.17910, 2024.04. |
| 2. |
Eiichi Ogawa, Letter: Entecavir versus tenofovir on serum lipoprotein levels of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy-Author's reply, Alimentary Pharmacology and Therapeutics, doi: 10.1111/apt.17693, 2023.10. |
| 3. |
Eiichi Ogawa, Yee Hui Yeo, Mindie H Nguyen, Immortal Time and Selection Biases in Study of Direct-Acting Antiviral Treatment and Hepatitis C Outcomes-Reply, JAMA Intern Med, doi: 10.1001/jamainternmed.2023.0557, 2023.04. |
| 4. |
Ogawa E, Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B - author's reply, Alimentary Pharmacology and Therapeutics, 10.1111/apt.17173, 2022.09. |
| 5. |
Sasaki K, Murata M, Nakamura K, Matsumoto Y, Nakashima Y, Yamasaki S, Ota A, Hiramine S, Takayama K, Ikezaki H, Toyoda K, Ogawa E, Shimono N, A case of severe COVID-19 with pulmonary thromboembolism related to heparin-induced thrombocytopenia during prophylactic anticoagulation therapy, Journal of Infection and Chemotherapy, 10.1016/j.jiac.2022.05.001, 2022.08. |
| 6. |
Ogawa E, Editorial: the role for PIVKA-II measurement after HCV elimination by direct-acting anti-virals in terms of prediction of hepatocellular carcinoma, Alimentary Pharmacology and Therapeutics, doi: 10.1111/apt.16696, 2022.01. |
| 7. |
Ogawa E, Editorial: FAST score‐ a new predictive marker for HCC after SVR- author's reply, Alimentary Pharmacology and Therapeutics, doi: 10.1111/apt.16032, 2020.09. |
| 8. |
Eiichi Ogawa, Mike T Wei, Mindie H Nguyen, Hepatitis B Virus Reactivation Potentiated by Biologics, Infectious Disease Clinics of North America, doi: 10.1016/j.idc.2020.02.009, 2020.06. |
| 9. |
Masaki Kakimoto, Masayuki Murata, Fujiko Mitsumoto-Kaseida, Eiichi Ogawa, Yuji Matsumoto, Akira Kusaga, Kazuhiro Toyoda, Takeo Hayashi, Kazuya Ura, Keishi Kanno, Norihiro Furusyo, Susumu Tazuma, Toxocarias is Suspected of Having Infiltrated Directly From the Liver to the Lung Through the Diaphragm, Internal Medicine, 2019.09. |
| 10. |
Ogawa E, Furusyo N, Nguyen MH, Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy, Drug Design, Development and Therapy, 10.2147/DDDT.S126742, 2017.11. |
| 11. |
Eiichi Ogawa, Norihiro Furusyo, Jun Hayashi, Commentary: Triple therapy for patients with chronic hepatitis C and advanced fibrosis? Authors' reply., Alimentary Pharmacology and Therapeutics, 2013.12. |
| 12. |
Eiichi Ogawa, Norihiro Furusyo, Jun Hayashi, Reply to: "Lower incidence of hepatocellular carcinoma in patients with transient virologic response to peginterferon and ribavirin combination therapy: Is it really the effect of the therapy?" , Journal of Hepatology, 2013.04. |
| 13. |
Ogawa E, Murata M, Unno M, Otaguro S, Kainuma M, Sawayama Y, Furusyo N, Yanai S, Matsumoto T, Hayashi J., Protein-losing enteropathy during highly active antiretroviral therapy in a patient with AIDS-related disseminated Mycobacterial avium complex infection., Journal of Infection and Chemotherapy, 2009.08. |
| 14. |
Ogawa E, Otaguro S, Murata M, Kainuma M, Sawayama Y, Furusyo N, Hayashi J., Intravenous immunoglobulin therapy for severe arthritis associated with human parvovirus B19 infection., Journal of Infection and Chemotherapy, 2008.10. |
